Huntington’s Disease Drugs Market Set To Grow To Over $800m In 2018

03 August 2018
Pharma

Visiongain has launched a new pharma report Global Huntington’s Disease Drugs Market Forecast 2018-2028: Forecasts by Drug Class (Antidopaminergics, Antipsychotics, Anticonvulsants, Antidepressants, Other) and Geography, with Analysis for Leading Drugs (Xenazine, Austedo, Clozapine, Haloperidol, Abilify), Leading Companies and Promising Pipeline Molecules

Huntington’s Disease is a progressive neurodegenerative disorder which can be inherited from one generation to another as an autosomal dominant trait. It arises due to genetically programmed degeneration of neurons in some parts of the brain such as basal ganglia and cerebral cortex. Basal ganglia play an important role in coordinating movement while cortex regulates perception, thought, and memory. Degeneration of neurons leads to progressive cognitive impairment and dementia. Huntington’s Disease has a broad impact on a person's functional abilities and usually results in movement, cognitive and psychiatric disorders. The most affected brain region is the striatum.

People suffering from Huntington’s Disease usually develop symptoms in their 30s and 50s. But the disease can emerge earlier or later in life. When the disease develops before age 20, the condition is called juvenile Huntington’s Disease. An earlier emergence of the disease often results in a different set of symptoms and faster disease progression. Medications are available to help manage the symptoms of Huntington’s Disease, but treatments can't prevent the physical, mental and behavioural decline associated with the condition.

The lead Visiongain report analyst for this report commented; ““The Global Huntington’s Disease market shows immense potential to grow in the future, growing in line with some emerging trends. One such trend is the increasing strategic partnerships in a move to introduce or diversify product portfolios pertaining to drugs. Another trend is advances in biomedical sciences and introduction of nanotechnologies in the global pharmaceutical market, which are revolutionising the development of medicines.

Lastly, the study of the pathogenesis of disease at genetic and molecular level have led to the discovery of new targets for therapy and producing disease modifying drugs.
There is a huge potential to tap the Huntington’s Disease market owing to high clinical & economic burden, the current lack of success rate of therapies, increasing patient awareness and physician education about HD.””

The Global market is highly competitive with many different players entering the market. The report discusses products from leading companies in the market. The report discusses products from leading companies in the market. Notable companies in the Huntington’s Disease market include Hoffmann-La Roche, H.Lundbeck, Teva Pharmaceutical Industries Prana Biotechnology, Sangamo Therapeutics Inc., Horizon Pharma, Omeros Corp. and Valeant Pharmaceuticals amongst others.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Rare Diseases Market Report 2021-2031

As lockdowns were imposed in all the countries, diagnosis rates went down in majority of countries during the year hitting the drug sales for some period. Although lockdown measures have been eased up in most countries by mid-year 2020, this trend is expected to continue beyond 2020, stock up of medicines by patients is likely to propel the drug sales in majority of the developed economies, which account for majority of rare diseases.

02 March 2021

Read

Visiongain Publishes Respiratory Inhalers Market Report 2021-2031

Product approval is a major milestone facing all key competitors in the respiratory inhalers market. Several strategies were implemented by key market players between 2015 and Jan 2021.

26 February 2021

Read

Visiongain Publishes Bile Duct Cancer Drugs Market Report to 2031

The global bile duct cancer drug market has been growing considerably owing to the rising incidence and prevalence rate of bile duct cancer patients worldwide, technological advancement in drug development, and healthcare spending.

22 February 2021

Read

Visiongain Publishes Big Data Analytics in Healthcare Market Report to 2031

The global Big Data Analytics in Healthcare market has been growing considerably owing to the rising technological advancement, growing investment, and cohesive government policies.

22 February 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever